Voya Investment Management LLC Sells 21,577 Shares of Zoetis Inc. $ZTS

by · The Markets Daily

Voya Investment Management LLC decreased its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 19.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 87,809 shares of the company’s stock after selling 21,577 shares during the period. Voya Investment Management LLC’s holdings in Zoetis were worth $12,848,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis during the 1st quarter worth about $25,000. 1248 Management LLC bought a new stake in Zoetis during the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the first quarter worth approximately $29,000. REAP Financial Group LLC raised its stake in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC boosted its holdings in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS opened at $123.62 on Tuesday. The company has a fifty day moving average price of $128.49 and a two-hundred day moving average price of $143.99. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The firm has a market capitalization of $54.48 billion, a PE ratio of 20.81, a P/E/G ratio of 2.66 and a beta of 0.97. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is 33.67%.

Wall Street Analyst Weigh In

ZTS has been the subject of several research analyst reports. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. Stifel Nicolaus reduced their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. KeyCorp began coverage on shares of Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $160.18.

Read Our Latest Stock Report on Zoetis

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).